{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:14:25Z","timestamp":1768436065236,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bioorg.2024.107940","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T22:50:59Z","timestamp":1730674259000},"page":"107940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis and FXR partial agonistic activity of anthranilic acid derivatives bearing aryloxy moiety as therapeutic agents for metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"153","author":[{"given":"Cong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wa","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaojiao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieyun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangduan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107940_b0005","doi-asserted-by":"crossref","unstructured":"S.Wang, S. L. Friedman, Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), Sci. Transl. Med. 15(2023) eadi0759.","DOI":"10.1126\/scitranslmed.adi0759"},{"key":"10.1016\/j.bioorg.2024.107940_b0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2024.107940_b0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic opportunities for the treatment of NASH with genetically validated targets","volume":"79","author":"Lind\u00e9n","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2024.107940_b0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2024.107940_b0025","doi-asserted-by":"crossref","unstructured":"S. Mitra, A. De, A. Chowdhury, Epidemiology of non-alcoholic and alcoholic fatty liver diseases, Transl. Gastroenterol. Hepatol. 5(2020)16.","DOI":"10.21037\/tgh.2019.09.08"},{"key":"10.1016\/j.bioorg.2024.107940_b0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol"},{"key":"10.1016\/j.bioorg.2024.107940_b0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41430-021-00923-4","article-title":"Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank","volume":"76","author":"Inan-Eroglu","year":"2022","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.bioorg.2024.107940_b0040","doi-asserted-by":"crossref","unstructured":"S. Wei, L. Wang, P. C. Evans, S. Xu, NAFLD and NASH: etiology, targets and emerging therapies, Drug Discov. Today 29(2024)103910.","DOI":"10.1016\/j.drudis.2024.103910"},{"key":"10.1016\/j.bioorg.2024.107940_b0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC. Endocr. Disord."},{"key":"10.1016\/j.bioorg.2024.107940_b0050","doi-asserted-by":"crossref","unstructured":"S. A. Harrison, P. Bedossa, C. D. Guy, J. M. Schattenberg, R. Loomba, R. Taub, D. Labriola, S. E. Moussa, G. W.Neff, M. E. Rinella, Q. M. Anstee, M. F. Abdelmalek, Younossi, Z, S. J. Baum, S. Francque, M. R. Charlton, P. N. Newsome, N. Lanthier, I. Schiefke, A. Mangia, J. M. Peric\u00e0s, R. Patil, A. J. Sanyal, M. Noureddin, M. B. Bansal, N. Alkhouri, L. Castera, M. Rudraraju, V. Ratziu, A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis, N. Engl. J. Med. 390(2024) 497-509.","DOI":"10.1056\/NEJMoa2309000"},{"key":"10.1016\/j.bioorg.2024.107940_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.bioorg.2024.107940_b0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.apsb.2016.07.008","article-title":"Fatty liver diseases, bile acids, and FXR","volume":"6","author":"Zhu","year":"2016","journal-title":"Acta. Pharm. Sin. b."},{"key":"10.1016\/j.bioorg.2024.107940_b0065","doi-asserted-by":"crossref","unstructured":"X. Huang, X. Liu, Z. Li, Bile acids and coronavirus disease 2019, Acta. Pharm. Sin. B. 14(2024) 1939-1950.","DOI":"10.1016\/j.apsb.2024.02.011"},{"key":"10.1016\/j.bioorg.2024.107940_b0070","first-page":"298","article-title":"Targeting farnesoid X receptor for liver and metabolic disorders, Trends","volume":"13","author":"Fiorucci","year":"2007","journal-title":"Mol. Med."},{"key":"10.1016\/j.bioorg.2024.107940_b0075","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell. Res."},{"key":"10.1016\/j.bioorg.2024.107940_b0080","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/cells10113206","article-title":"The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity","volume":"10","author":"Anderson","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2024.107940_b0085","doi-asserted-by":"crossref","unstructured":"D. Q. Sun, F. Yuan, M. Z. Fu, M. Y. Zhong, S. L. Zhang Y. Lu, G. Targher, C. D. Byrne, M. H. Zheng, W. J. Yuan, Farnesoid X receptor activation protects against renal fibrosis via modulation of \u03b2-catenin signaling, Mol. Metab. 79(2024) 101841.","DOI":"10.1016\/j.molmet.2023.101841"},{"key":"10.1016\/j.bioorg.2024.107940_b0090","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41401-021-00849-4","article-title":"FXR: structures, biology, and drug development for NASH and fibrosis diseases","volume":"43","author":"Tian","year":"2022","journal-title":"Acta. Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2024.107940_b0095","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell."},{"key":"10.1016\/j.bioorg.2024.107940_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111678","article-title":"Recent advances on FXR-targeting therapeutics","volume":"552","author":"Panzitt","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2024.107940_b0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","article-title":"Bile acid nuclear receptor FXR and digestive system diseases","volume":"5","author":"Ding","year":"2015","journal-title":"Acta. Pharm. Sin. b."},{"key":"10.1016\/j.bioorg.2024.107940_b0110","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2024.107940_b0115","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2024.107940_b0120","first-page":"623","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH), Expert. Opin. Investig","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Drugs."},{"key":"10.1016\/j.bioorg.2024.107940_b0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cld.1076","article-title":"Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis","volume":"17","author":"Ratziu","year":"2021","journal-title":"Clin. Liver. Dis."},{"key":"10.1016\/j.bioorg.2024.107940_b0130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2024.107940_b0135","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"39","author":"Younossi","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.bioorg.2024.107940_b0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2024.107940_b0145","first-page":"2148","article-title":"Farnesoid X receptor (FXR): Structures and ligands, Comput. Struct","volume":"19","author":"Jiang","year":"2021","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.bioorg.2024.107940_b0150","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1021\/acs.jmedchem.2c00641","article-title":"Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis","volume":"65","author":"Shim","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107940_b0155","doi-asserted-by":"crossref","unstructured":"M. J. Genin, A. B. Bueno, J. Agejas Francisco, P. R. Manninen, W. P. Bocchinfuso, C. Montrose-Rafizadeh, E.A. Cannady, T.M. Jones, J.R. Stille, E. Raddad, C. Reidy, A.Cox, M.D. Michael, L.F. Michael. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia, J. Med. Chem. 58(2015) 9768-9772.","DOI":"10.1021\/acs.jmedchem.5b01161"},{"key":"10.1016\/j.bioorg.2024.107940_b0160","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107940_b0165","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and challenges of selective Farnesoid X Receptor modulation","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2024.107940_b0170","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.bmc.2014.02.053","article-title":"Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)","volume":"22","author":"Merk","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107940_b0175","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.1021\/jm500937v","article-title":"Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist","volume":"57","author":"Merk","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107940_b0180","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bmc.2014.12.013","article-title":"Anthranilic acid derivatives as nuclear receptor modulators\u2013development of novel PPAR selective and dual PPAR\/FXR ligands","volume":"23","author":"Merk","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107940_b0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11030-018-9843-2","article-title":"Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists","volume":"23","author":"Nian","year":"2019","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2024.107940_b0190","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1038\/s41467-019-10853-2","article-title":"Molecular tuning of farnesoid X receptor partial agonism","volume":"10","author":"Merk","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2024.107940_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115992","article-title":"Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis","volume":"264","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107940_b0200","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bioorg.2024.107940_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000527471","article-title":"Free Fatty Acids Induce Lipid Accumulation, Autophagy, and Apoptosis in Human Sebocytes","volume":"36","author":"Hossini","year":"2023","journal-title":"Skin Pharmacol. Physiol."},{"key":"10.1016\/j.bioorg.2024.107940_b0210","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.1021\/acs.jmedchem.0c01065","article-title":"Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107940_b0215","first-page":"1273","article-title":"Aptasensors Are Conjectured as Promising ALT and AST Diagnostic Tools for the Early Diagnosis of Acute Liver Injury","volume":"13","author":"Chinnappan","year":"2023","journal-title":"Life (basel)."},{"key":"10.1016\/j.bioorg.2024.107940_b0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bioorg.2024.107940_b0225","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450116666150427155342","article-title":"Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease","volume":"16","author":"Liu","year":"2015","journal-title":"Curr. Drug. Targets."},{"key":"10.1016\/j.bioorg.2024.107940_b0230","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.numecd.2005.05.003","article-title":"A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress","volume":"15","author":"Del","year":"2005","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.bioorg.2024.107940_b0235","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1111\/liv.14205","article-title":"Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion","volume":"39","author":"Eriksen","year":"2019","journal-title":"Liver. Int."},{"key":"10.1016\/j.bioorg.2024.107940_b0240","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.devcel.2023.07.001","article-title":"Parallel CRISPR-Cas9 screens identify mechanisms of PLIN2 and lipid droplet regulation","volume":"58","author":"Roberts","year":"2023","journal-title":"Dev. Cell."},{"key":"10.1016\/j.bioorg.2024.107940_b0245","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/acs.jmedchem.3c00996","article-title":"Discovery of Novel Inhibitors of BRD4 for Treating Prostate Cancer: A Comprehensive Case Study for Considering Water Networks in Virtual Screening and Drug Design","volume":"67","author":"Zhong","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107940_b0250","first-page":"1","article-title":"Understanding the impact of binding free energy and kinetics calculations in modern drug discovery","volume":"9","author":"Adediwura","year":"2024","journal-title":"Expert. Opin. Drug. Discov."},{"key":"10.1016\/j.bioorg.2024.107940_b0255","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/mc.22571","article-title":"Exploiting agonist biased signaling of chemokines to target cancer","volume":"56","author":"Roy","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2024.107940_b0260","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3390\/pharmaceutics14102068","article-title":"Post-Injury Buprenorphine Administration Is Associated with Long-Term Region-Specific Glial Alterations in Rats","volume":"14","author":"Ryu","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.bioorg.2024.107940_b0265","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/cells11182854","article-title":"Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model","volume":"11","author":"Najimi","year":"2022","journal-title":"Cells."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:28:38Z","timestamp":1738204118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824008459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":53,"alternative-id":["S0045206824008459"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107940","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and FXR partial agonistic activity of anthranilic acid derivatives bearing aryloxy moiety as therapeutic agents for metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107940"}}